The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Guidance on managing diarrhea with zanidatamab-based regimens in gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, describes consensus recommendations from a modified Delphi panel addressing diarrhea management with zanidatamab plus chemotherapy, with or without tislelizumab, based on data from the HERIZON-GEA-01 trial (NCT05152147) in HER2-positive advanced gastroesophageal adenocarcinoma. Diarrhea, often occurring early in treatment, was identified as the most clinically significant toxicity. Panelists reached strong consensus supporting baseline risk assessment, early patient education, proactive loperamide prophylaxis. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
